Literature DB >> 30688147

Positive Allosteric Modulation of Cholinergic Receptors Improves Spatial Learning after Cortical Contusion Injury in Mice.

Daniel P Holschneider1,2,3, Yumei Guo1, Zhuo Wang1, Milagros Vidal1, Oscar U Scremin3.   

Abstract

We examined benzyl quinolone carboxylic acid (BQCA), a novel M1 muscarinic-positive allosteric modulator, for improving memory and motor dysfunction after cerebral cortical contusion injury (CCI). Adult mice received unilateral motorsensory cortical CCI or sham injury. Benzyl quinolone carboxylic acid (BQCA; 5, 10, and 20 mg/kg, intraperitoneally [i.p.] × 2/day × 3-4 weeks) or vehicle (Veh) were administered, and weekly evaluations were undertaken using a battery of motor tests, as well as the Morris water maze. Thereafter, cerebral metabolic activation was investigated in awake animals during walking with [14C]-2-deoxygIucose autoradiography, comparing CCI mice previously treated with BQCA (20 mg/kg) or vehicle. Relative changes in local cerebral glucose uptake (rCGU) were evaluated in three-dimensional-reconstructed brains using statistical parametric mapping. CCI resulted in mild hyperactivity in the open field, and modest significant motor deficits, as well as significantly decreased spatial learning at 3 weeks. BQCA in CCI mice resulted in significantly improved spatial recall during the third week, with minimal effects on motor outcomes. CCI significantly decreased rCGU in the ipsilesional basal ganglia-thalamocortical circuit and in somatosensory regions, with relative increases noted contralaterally, as well as in the cerebellum. Significant decreases in rCGU were noted in subregions of the ipsilesional hippocampal formation, with significant increases noted contralesionally. BQCA compared to vehicle-treated mice showed modest, though significantly increased, rCGU in motor regions, as well as a partial reversal of lesion-related rCGU findings in subregions of the hippocampal formation. rCGU in ipsilesional posterior CA1 demonstrated a significant inverse correlation with latency to find the submerged platform. BQCA at 20 mg/kg had no significant effect on general motor activity, body weight, or acute motor, secretory, or respiratory symptoms. Results suggest that BQCA is a candidate compound to improve learning and memory function after brain trauma and may not suffer the associated central nervous system side effects typically associated with even modest doses of other cholinergic enhancers.

Entities:  

Keywords:  acetylcholine; cerebral metabolism; cholinergic; cortical contusion injury; memory; mice; motor function; positive allosteric modulators; spatial navigation; traumatic brain injury

Mesh:

Substances:

Year:  2019        PMID: 30688147      PMCID: PMC6653801          DOI: 10.1089/neu.2018.6036

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  51 in total

Review 1.  A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury.

Authors:  Stefanie L Griffin; Robert van Reekum; Cheryl Masanic
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

2.  Statistical parametric mapping applied to an autoradiographic study of cerebral activation during treadmill walking in rats.

Authors:  Peter T Nguyen; Daniel P Holschneider; Jean-Michel I Maarek; Jun Yang; Mark A Mandelkern
Journal:  Neuroimage       Date:  2004-09       Impact factor: 6.556

3.  Changes in sensitivity of cholinoceptors and adrenoceptors during transhemispheric cortical reorganisation in rat SmI.

Authors:  M Zarei; V V Raevsky; G S Dawe; J D Stephenson
Journal:  Brain Res       Date:  2001-01-12       Impact factor: 3.252

4.  Lack of protection of monoamine oxidase B-deficient mice from age-related spatial learning deficits in the Morris water maze.

Authors:  D P Holschneider; O U Scremin; K Chen; J C Shih
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

5.  Spatial normalization of brain images with focal lesions using cost function masking.

Authors:  M Brett; A P Leff; C Rorden; J Ashburner
Journal:  Neuroimage       Date:  2001-08       Impact factor: 6.556

6.  Transhemispheric cortical reorganization in rat SmI and involvement of central noradrenergic system.

Authors:  M Zarei; J D Stephenson
Journal:  Brain Res       Date:  2000-07-07       Impact factor: 3.252

7.  Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury.

Authors:  Lei Zhang; Rosette C Plotkin; Gary Wang; M Elizabeth Sandel; Shuko Lee
Journal:  Arch Phys Med Rehabil       Date:  2004-07       Impact factor: 3.966

Review 8.  The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

Authors:  F Inglis
Journal:  Int J Clin Pract Suppl       Date:  2002-06

9.  Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

Authors:  Iracema Leroi; Jason Brandt; Stephen G Reich; Constantine G Lyketsos; Stephen Grill; Richard Thompson; Laura Marsh
Journal:  Int J Geriatr Psychiatry       Date:  2004-01       Impact factor: 3.485

Review 10.  Acetylcholine modulation of neural systems involved in learning and memory.

Authors:  Paul E Gold
Journal:  Neurobiol Learn Mem       Date:  2003-11       Impact factor: 2.877

View more
  2 in total

1.  A gut-derived metabolite alters brain activity and anxiety behaviour in mice.

Authors:  Brittany D Needham; Masanori Funabashi; Mark D Adame; Zhuo Wang; Joseph C Boktor; Jillian Haney; Wei-Li Wu; Claire Rabut; Mark S Ladinsky; Son-Jong Hwang; Yumei Guo; Qiyun Zhu; Jessica A Griffiths; Rob Knight; Pamela J Bjorkman; Mikhail G Shapiro; Daniel H Geschwind; Daniel P Holschneider; Michael A Fischbach; Sarkis K Mazmanian
Journal:  Nature       Date:  2022-02-14       Impact factor: 69.504

Review 2.  Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sean P Moran; James Maksymetz; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-11-08       Impact factor: 14.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.